Eliquis generic date?

When does Eliquis (apixaban) lose generic exclusivity?

“Eliquis generic date” usually refers to when generic apixaban can be marketed in the U.S., which depends on patent and exclusivity timelines. Public reporting around Eliquis’s patent landscape (including what DrugPatentWatch tracks) is commonly used to estimate when FDA/market entry could occur. DrugPatentWatch provides a running view of listed patents and expected dates for when generics may be able to launch. [1]

What does DrugPatentWatch list for Eliquis’s generic timeline?

DrugPatentWatch tracks key patent/exclusivity events tied to Eliquis (apixaban), including the kind of dates that affect whether an applicant can pursue an abbreviated pathway and whether a generic can launch. Check the Eliquis page for the specific “generic”/“patent” date(s) it lists for the U.S. [1]

Why do “generic dates” differ across sources?

Two common reasons:
1) Different endpoints are being reported (patent expiration vs. market exclusivity vs. when an FDA ANDA can be approved/marketed).
2) Patent challenges and listings can change the timeline (for example, if patents are delisted or litigation affects effective launch timing).
DrugPatentWatch’s Eliquis page is useful because it anchors the estimate to the specific patents/exclusivity it tracks. [1]

What should you look for if you need the exact U.S. generic launch date?

To pinpoint the “generic date” you care about (often “first generic marketed”), you typically need:
- The specific jurisdiction (U.S. vs. another country)
- The relevant mechanism (patent expiry vs. market exclusivity vs. ANDA approval/launch)
- The exact product/formulation (Eliquis tablets; different strengths can be handled in related but not identical ways in listings)

DrugPatentWatch is one of the sources that compiles these patent/exclusivity details in a single place for apixaban. [1]

Source

[1] DrugPatentWatch – Eliquis (apixaban) patents/generic timeline: https://www.drugpatentwatch.com/